colorectal cancer

[Oncogene] Scientists reported that both PD-L1 and JMJD2D were frequently overexpressed in human colorectal cancer specimens with a significant positive correlation.

[iScience] Scientist analyzed immune subtypes and immune evasion via neoantigen-related mechanisms. They identified a distinctive cancer subtype characterized by immune evasion and very poor overall survival.

[Fate Therapeutics, Inc.] Fate Therapeutics, Inc. announced that the US FDA has cleared the company’s Investigational New Drug application for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor NK cell product candidate.

[iScience] To understand the systemic immune response in advanced untreated primary colorectal cancer, researchers analyzed immune subtypes and immune evasion via neoantigen-related mechanisms.

[Scientific Reports] Researchers explored the involvement of epithelial GPR120 in the colorectal cancer development. Both in vitro and in vivo experiments were conducted to mimic the conditional deletion of the receptor from gut epithelium.

[Cellular Signalling] Scientists analyzed Clinical Proteomic Tumor Analysis Consortium, colon tissue microarray, and colon cancer cells to evaluate the ESRP1 expression levels in colorectal cancer subtypes.